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Abstract:  Differentiation of idiopathic Parkinson’s disease from other causes of Parkinsonism, such as 
Multiple System Atrophy, Progressive Supranuclar Palsy and Vascular Parkinsonism can be difficult. 
Clinicopathological studies suggest that the clinical diagnosis of idiopathic Parkinson’s disease is 76% 
reliable. Also, clinical differentiation of tremor prominent Parkinsonism from Essential Tremor or Drug induced 
Parkinsonism may be problematic, especially in the early stages of the disease. Since these disorders are 
obviously different in clinical progress, it is important for the clinician to address the patient’s and family’s 
concerns about prognosis from a firm diagnostic footing. In this article the clinical features of the common and 
important causes of Parkinsonism and tremor disorders are reviewed and a practical approach is suggested. 
Key Words: Idiopathic Parkinson’s Disease, Multiple System Atrophy, Progressive Supranuclar Palsy, Vascular 
Parkinsonism, Essential Tremor, Drug induced Parkinsonism. 
 
Introduction 
James Parkinson first described Parkinson’s 
disease in 1817 in his famous Essay on the 
“Shaking Palsy” [1]. Since then there have been 
huge developments and changes in the 
understanding of the pathophysiology, clinical 
features and treatment of the disease, which 
carries his name. However, the diagnosis is still a 
clinical one and there are no biological markers to 
diagnose this condition. In the majority of patients 
the diagnosis of idiopathic Parkinson’s disease 
seems straightforward. However, many patients 
with Parkinsonism and tremor disorders exhibit a 
diagnostic challenge particularly in the early stage 
of the illness. Clinico-pathological studies have 
shown that 24% of patients with a clinical 
diagnosis of idiopathic Parkinson’s disease (made 
by a neurologist or geriatrician) do not fulfil 
pathological criteria and have an alternative 
diagnosis [2,3]. Multiple system atrophy, 
progressive supranuclar palsy and vascular 
disease are the main pathological diagnoses in 
such cases. The bias introduced by these 
pathological studies when compared to a clinical 
setting is in the absence of essential tremor and 
drug induced Parkinsonism.  
Why is it important to differentiation between 
idiopathic Parkinson’s disease and other causes of 
Parkinsonism and tremor disorders especially in 
the early stages? Firstly, there are differences in 
clinical progress and survival from the more 
benign essential tremor through idiopathic 
Parkinson’s disease to multiple system atrophy or 
progressive supranuclar palsy. Therefore, it is 
appropriate for the clinician to address the 
patient’s and family’s concern about prognosis and 
provide accurate prognostic information. Secondly, 
introduction and amendment of drug therapy is 
tailored to the patients’ condition and progress, 
e.g. patients suspected to have idiopathic 
Parkinson’s disease in whom a revised diagnosis 
of essential tremor is reached, can have levodopa 
withdrawal. Finally, an accurate diagnosis would 
help in understanding the aetiology and 
pathophysiology of different causes of 
Parkinsonism and tremor disorders, and define 
accurately a patient cohort for clinical research 
studies.  
In this article the clinical features of idiopathic 
Parkinson ’s disease (PD), Multiple System 
Atrophy (MSA), Progressive Supranuclar Palsy 
(PSP) and Vascular Parkinsonism (VP) as well as 
Essential Tremor (ET) and Drug Induced 
Parkinsonism (DIP) will be discussed.  
Definition and classification of parkinsonism: 
Parkinsonism is a clinical syndrome characterised 
by bradykinesia: slowness of movement, 
hypokinesia: reduced movement, akinesia: loss of 
movement, rigidity: increased resistance to 
passive extension and flexion, tremor: mainly 
resting.  
Parkinsonism may be classified as: 
1. Idiopathic Parkinson’s disease, of unknown 
aetiology. 
2. Parkinsonism as part of other 
neurodegenerative disorders, such as MSA, PSP. 
3. Parkinsonism with identifiable causes, such 
as VP and DIP. 
Idiopathic Parkinson’s Disease (PD): Idiopathic 
Parkinson’s disease consists of Parkinsonism 
characterised pathologically by neuronal loss with 
Lewy bodies in the substantia nigra. Lewy bodies, 
which are eosinophilic intracytoplasmic inclusions 
first described by F H Lewy in 1914, are not 
specific for PD. Other conditions such as MSA, 
PSP, and Lewy body dementia were shown to 
have Lewy bodies. Also, Lewy bodies can be 
found as an incidental finding in elderly patients 
without clinical features of PD, which probably 
represent pre-clinical or early stages of PD [4-7]. 
Idiopathic Parkinson ’s disease is the common 
cause of parkinsonism, with an annual incidence 
of 20.5 per 100 000 of the population and 
prevalence 164 per 100 000 [8-10]. The 
prevalence of the disease increases with age from 
47 per 100 000 for ages 40-49 years, to 832 per 
100 000 for 70-79 years [10]. The mean age at 
onset PD is between 55-65 years, with a slight 
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male predominance of 60%, and mean age of 
death is 75.5 years [10-12].  
The majority of patients with Parkinson’s disease 
have no family history of Parkinsonism. However, 
some patients with positive family history could 
have the familial form of Parkinsonism especially 
patients with young onset disease. Several genetic 
variants have been identified such as the parkin 
gene in both autosomal recessive and dominant 
forms. Some of these cases do not have Lewy 
bodies. Over the next few years the understanding 
of the genetics of Parkinsonism would modify our 
views about the aetiology of PD [13,14]. 
Patients usually present with non-specific pains 
and aches, stiffness, changes in the handwriting, 
or general slowing down. Examination usually 
shows loss of arm swing, tendency to drag a leg, 
difficulty with hand movements, loss of facial 
expression, reduced voice volume, lead-pipe 
rigidity or cog-wheel rigidity if tremor is 
superimposed and tremor mainly at rest. The 
onset is asymmetric in 72% of the patients. Tremor 
is the presenting features in 70% of patients but 
42% have tremor only without bradykinesia or 
rigidity and 11% have tremor dominant disease 
hence the name Benign Tremulous Parkinson’s 
disease, which has a better prognosis than the 
akinetic rigid presentation. In the late stages of PD 
patients develop speech and swallowing 
difficulties. Also, falls, gait problems, autonomic 
dysfunction and dementia (up to 40%) are late 
features. Almost every patient with PD responds to 
levodopa therapy [11]. 
 
Table 1:  Summary of clinical features of idiopathic PD 
- Three Subtypes: Tremor dominant (26%), 
- Akinetic-rigid (38%) and - Mixed type (36%). 
- Bradykinesia and tremor and/or rigidity. 
  - Unilateral onset with persistent asymmetry affecting 
the side of the onset most (Hemi-parkinsonism). 
- Arms are more involved than legs. 
- Excellent response to levodopa. 
 
Multiple System Atrophy (MSA) 
MSA is a sporadic, adult onset, 
neurodegenerative disease. It is a clinico-
pathological entity, which can present with any 
combination of Parkinsonism, cerebellar and/or 
pyramidal signs and autonomic dysfunction. 
Pathologically, it is characterised by cell loss and 
gliosis and α-synuclein positive oligodendroglial 
cytoplasmic inclusions in a selection of brain 
structures such as: substantia nigra, striatum, 
locus coeruleus, pontine nuclei, cerebellar purkinje 
cells, inferior olives, and Onuf’s nucleus in the 
spinal cord [15-18]. 
Shy and Drager described in 1960 a 
neurological syndrome associated with orthostatic 
hypotension [19]. In 1969, Graham and 
Oppenheimer introduced the term MSA, [20] but it 
has since become a title, which covers a wide 
range of different degenerative conditions [15].  
 
The following subtypes of MSA have been 
defined in a clinico-pathological study: [21]. 
(i) Shy-Drager syndrome, in which autonomic 
failure predominates. 
(ii) Striatonigral degeneration, in which 
Parkinsonism predominates. 
(iii) Olivopontocerebellar atrophy, in which 
cerebellar features predominate. 
However, Oertel and Quinn [22] argue against 
using the term Shy-Drager syndrome because 
autonomic dysfunction is almost universal in MSA. 
[21] They define MSA subtypes as follows: 
(i) Striatonigral degeneration (MSA-parkinsonian 
type or MSA-P). 
(ii) Sporadic olivopontocerebellar atrophy (MSA-
cerebellar type or MSA-C). 
There are no definite incidence figures for this 
disorder and it has been postulated that MSA 
contributes between 3.6 and 22% of incident 
cases of parkinsonism [15, 16,19-24]. MSA-P is 2 
to 4 times more common than MSA-C. MSA is 
slightly more common in male patients, with a 
mean age of onset of 54 years, mean age at death 
of 60 years and mean duration of illness of 6-9 
years [23,24].  
Autonomic dysfunction is usually present in 
almost all patients and impotence is the most 
common feature in males. Postural faintness, 
urinary incontinence and/or urinary retention are 
other features. Half of the cases have cerebellar 
signs, mainly gait ataxia, and pyramidal signs can 
be demonstrated in 50% of MSA patients. 
Parkinsonism occurs in the majority of cases, with 
akinesia as the more common feature, rest tremor 
in less than half of cases and classical pill-rolling 
tremor seen only in 10% of patients. Other 
features included stridor and muscular 
contractions while dementia is rarely a feature of 
MSA. Only a third of patients show some 
response to levodopa, which is usually 
unsustainable [23,24]. 
 
Table 2- Summary of clinical features of MSA 
- Two Subtypes: MSA-P and MSA-C. 
- Mainly symmetrical bradykinesia and rigidity. 
- Features of autonomic dysfunction. 
- Cerebellar signs and pyramidal signs. 
- Stridor, and muscular contractions. 
- Dementia is rare. 
- Poor response to levodopa 
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Progressive Supranuclear Palsy (PSP) or 
Steele-Richardson-Olszweski Syndrome 
In 1964 Steele, Richardson and Olszewski 
described the clinical and pathological features of 
nine patients with a progressive disorder of vertical 
gaze, axial rigidity, dysarthria, pseudobulbar palsy 
and mild dementia, which they called progressive 
supranuclear palsy [25]. Pathologically PSP is 
characterised by the presence of neurofibrillary 
tangles and neuropil threads and tufted astrocytes 
within the following areas: pallidum, subthalamic 
nucleus, substantia nigra, midbrain and pontine 
reticular formation. These distinctive 
histopathological inclusions are made up of 
insoluble aggregation of tau phosphoprotein. Tau-
positive glial inclusions are a pathological feature 
of PSP [26]. 
PSP is under-diagnosed, making accurate 
epidemiological data difficult to obtain. Several 
studies showed a prevalence between 1.39 to 6.5 
per 100 000 [27,28]. Annual incidence of 3.1 to 4.0 
cases per million has been estimated in one study 
[27].
  
PSP is a sporadic disorder, but familial cases 
have been described [29, 30]. It is slightly more 
common in males and usually presents in the 
seventh decade. Postural instability and falling are 
the presenting features in more than 50% of 
patients, and dysarthria in one third. Visual 
disturbances in the form of diplopia, blurred vision, 
burning eyes, and light sensitivity are the initial 
symptoms in around 15% of patients. Cognitive or 
behavioural changes generally follow [31-33].
 
Other clinical features include; bilateral 
bradykinesia, axial rigidity, speech changes 
(dysphonic, palilalia, ataxic and unintelligible 
speech), frontal lobe symptoms, personality 
changes, dysphagia and neck dystonia [34]. 
Vertical downward palsy is the single most 
important clinical feature of PSP. Although upward 
gaze and convergence become impaired, this also 
occurs in other basal ganglia disorders and in old 
age [31]. The oculocephalic manoeuvre remains 
intact (except in very advanced stages), and it is 
this characteristic that makes the disorder 
supranuclear [35, 36].
 Other ocular manifestations 
include supranuclear ophthalmoplegia, absent 
Bell’s phenomenon, impaired pupillary light 
reflexes, lid retraction, a markedly reduced blink 
rate, frontalis muscle overactivity, blepharospasm, 
and apraxia of eye opening or closure [31, 37]. 
These changes give the patient a fixed, staring, 
and astonished expression [31]. Although the 
presence of down-gaze palsy is an essential 
finding to secure the diagnosis of PSP, there are a 
few pathologically proven cases reported who had 
not developed such abnormality during life [34,37]. 
 
Table 3: Summary of clinical features of PSP 
- Postural instability and falls. 
- Symmetrical bradykinesia and rigidity. 
- Cognitive or behavioural. 
- Dysarthria and speech changes. 
- Vertical downward palsy with intact oculocephalic 
manoeuvre. 
- Poor response to levodopa 
 
Vascular Parkinsonism (VP) 
The concept of VP was introduced when Critchley in 
1929 described 5 types of clinical presentations of what 
was termed arteriosclerotic Parkinsonism [38]. Rigidity, 
fixed faces and short-stepping gait were the main 
clinical signs. Pseudo-bulbar, dementia, incontinence, 
pyramidal or cerebellar signs were considered as 
additional features. After several clinical studies in the 
1960’s and 1970’s showed no relation between 
arteriosclerosis and PD, Critchley in 1981 renamed the 
condition arteriosclerotic pseudo- parkinsonism [39-42]. 
With the development of CT and MRI the concept of VP 
was revived, but there are no generally accepted clinical 
criteria to diagnose this condition [43-45]. 
Several clinical features have been described relating 
brain vascular lesions to Parkinsonism. An insidious 
onset of parkinsonism, at times indistinguishable from 
PD, including a response to levodopa, due to brain 
vascular infarcts has been described [3,12,44-47]. On 
the other hand, two patients presented with acute onset 
Parkinsonism, due to vascular lesions in the basal 
ganglia, and recovery without anti-parkinsonian drugs 
had been reported [48,49].  
Lower body Parkinsonism (LBP) is another term used 
to describe patients with VP and it represents a group of 
patients, probably hypertensive, who usually have gait 
difficulty, symmetrical rigidity, absent tremor, and no or 
some response to levodopa therapy [50-52]. 
The association of ischaemic stroke and vascular risk 
factors was addressed in two studies, where the 
incidence of ischaemic stroke among PD patients was 
lower than controls in one study but an association was 
found in another [53-54]. Thus PD may co-exist with 
cerebrovascular disease, but there may be a lower 
probability of a chance association because of the risk 
factor profiles for each disease. Post-mortem studies 
provide definite evidence that PD patients may also 
have cerebrovascular disease, and that patients with 
parkinsonism may have cerebrovascular disease but no 
pathological features of PD [3]. The clearest clinical 
description of Parkinsonism in association with 
cerebrovascular disease is that of LBP. However, upper 
body signs and symptoms are not excluded in such 
patients, and a vascular aetiology for patients with less 
than pure lower body features appears possible.  
Finally, a small subset of patients may be unfortunate 
enough to have predominately upper body features from 
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Table 4: Summary of clinical features of VP 
- Gait difficulty, symmetrical rigidity, absent tremor 
(lower body Parkinsonism). 
- An insidious onset of parkinsonism indistinguishable 
from PD. 
- Acute onset parkinsonism, due to vascular lesions 
in the basal ganglia. 
- Modest or poor response to levodopa. Occasionally 
good response. 
 
Essential Tremor (ET) 
Essential tremor is the most common movement 
disorder, with a worldwide prevalence estimated at 
between 4 and 39 per 1000. The annual incidence 
is about 23 per 100 000 population [55, 56]. A 
bimodal distribution with peaks in the second and 
fifth decades has been reported with men and 
women equally affected, [57,58] but other studies 
indicate an onset usually around 45 years with an 
earlier onset in familial cases [59]. Penetrance is 
usually complete by the age of 65 years, and no 
evidence of the disease skipping a generation was 
found in studying 20 kindreds, thereby indicating 
autosomal dominant inheritance [58]. However, no 
responsible gene has yet been identified [60]. 
Typically the tremor is postural and therefore 
occurring while voluntarily maintaining position 
against gravity and mainly involving hands and 
forearm, starting intermittently and progressing to 
become permanent, rarely remitting and usually 
worsened by emotion [61]. Tremor of the head, 
voice, tongue, and legs may follow [57,58]. ET is 
different from parkinsonian tremor, which is mainly 
resting and therefore occurs in muscles, which are 
completely supported against gravity [62, 63]. 
Although this description implies a clear separation 
of the tremor types, there is often a degree of 
overlap making ET one of the conditions which is 
most commonly misdiagnosed as PD, especially 
with less experienced physicians [64]. It is 
important to remember, “No single type of tremor 
can be pathognomonic of a particular disorder” 
[63].
  
There is conflicting evidence from the literature 
about the association between ET and PD, several 
studies showing no evidences of an association 
[56,58,59,64-66]
 and others suggesting otherwise 
[57,67,68]. There are no specific pathological 
features of ET [69, 70]. 
It is commonly stated that 30 to 50% of ET 
patients have an affected relative, [64, 71] 
however, reviewing all service-based and 
community-based published studies of familial 
aggregation in ET found that a range of 17-100% 
of patients reported affected relatives, clearly 
suggesting variation in data collection techniques 
[72].
 Also, ET is sometimes described as benign, 
and although it does not affect life expectancy, it 
can impair physical function such as the ability to 
eat, drink, and write and can be a social 
embarrassment [73,74]. Up to 15% of patients 
take early retirement as a result of the disability 
caused by the tremor [75].  
As many as 50-66% of ET patients report an 
improvement in their tremor after consuming 
alcohol [57,58,76,77]. Although this was also 
reported in one study for parkinsonian tremor, [78] 
it was not reproduced in another study [79].  
Treatment is mainly with beta-blockers 
particularly propranolol up to a dose of 320mg 
daily [61]. Primidone can have a beneficial effect 
but the majority of patients do not tolerate it [80]. 
 
Table 5: Summary of clinical features of ET 
- Mainly postural tremor but an overlap with resting 
tremor can be seen. 
- No rigidity or bradykinesia. 
- Positive family history. 
- Improvement with alcohol. 
- Treatment mainly with beta blockers particularly 
propranolol 
 
Drug Induced Parkinsonism (DIP 
DIP is the most frequent neuroleptic induced 
side effect. Both Phenothiazines and non-
phenothiazines can induce parkinsonism in 10-
15% of psychotic patients treated with these drugs 
[81,82]. Anti-emetic drugs such as 
prochlorperazine and metoclopramide can cause 
Parkinsonism [83-85]. Other drugs such as 
sodium valproate, tetrabenazine and calcium-
channel blockers such as cinnarizine are also 
reported to cause DIP [86-88]. DIP unmasked PD 
can be difficult to distinguished from pure DIP, 
especially that DIP could take some months if not 
years to reverse on withdrawal of the offending 
drug [89]. Stopping the offending drug is obviously 
the treatment of choice in DIP however; this could 
be difficult especially with neuroleptic drugs. 
Anticholinergic, amantadine and pyridoxine may 
help in reducing the parkinsonian symptoms in 
patients with DIP [90,91] 
 
Table 6- Summary of clinical features of DIT 
- Neuroleptic drugs are the most frequent cause of 
DIP. 
- If possible the offending drug should be stopped. 
- Parkinsonism can take a long time to resolve after 
stopping the offending drugs. 




Parkinsonism and tremor disorders could 
represent a diagnostic challenge. However, a 
good clinical assessment usually helps in reaching 
a final diagnosis but sometimes the patient needs 
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to be assessed several times before a clear 
diagnosis emerges due to lack of diagnostic 
investigation. 
The clinicians should be alert to the unusual 
symptoms and signs such as: a) Absent or poor 
response to levodopa, b) Rapid disease 
progression, c) Autonomic failure, d) Early falls, e) 
Cerebellar and/or pyramidal signs, f) Supranuclear 
palsy, g) Lower body Parkinsonism, h) Early 
dementia.  
I suggest the following practical approaches to 
patients presenting with parkinsonism and/or 
tremor:  
1) Confirm that the patient has parkinsonian 
features, 2) Always think of essential tremor when 
tremor is the prominent feature and there is no gait 
problem nor difficulty to rise from a low chair, 3) 
Ask about drug history, 4) Ask about symptoms of 
autonomic dysfunction, 5) Ask about early falls, 6) 
Check for pyramidal and cerebellar signs, 7) 
Measure the blood pressure, supine and erect, 8) 
Check eye movements, 9) Check the Mini-mental 
test, 10) If not sure whether the patient has PD or 
other diseases (MSA, PSP, VP) try L-dopa. 
With being alert to the unusual features and 
following a systemic approach the likelihood of 
getting the diagnosis right is high although this 
may take some time. 
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